4D Molecular Therapeutics (FDMT) Short-term Investments (2021 - 2026)

4D Molecular Therapeutics (FDMT) has reported Short-term Investments for 6 consecutive years, with $318.4 million the latest figure, recorded in Q1 2026.

• In Q1 2026, Short-term Investments rose 69.44% year-over-year to $318.4 million; the TTM figure through Mar 2026 stood at $318.4 million (up 69.44% YoY), while the FY2025 annual figure was $342.4 million, up 24.27% from the prior year.
• Short-term Investments slipped to $318.4 million in Q1 2026 per FDMT's latest filing, from $342.4 million in the prior quarter.
• Across five years, Short-term Investments topped out at $352.9 million in Q2 2024 and bottomed at $39.1 million in Q4 2023.
• Historically, Short-term Investments has averaged $197.8 million across 5 years, with a median of $187.9 million in 2025.
• Annual changes were most pronounced in 2023 — Short-term Investments plunged 75.73% — and 2024, when it soared 614.67%.
• 4D Molecular Therapeutics' Short-term Investments stood at $161.2 million in 2022, then slumped by 75.73% to $39.1 million in 2023, then surged by 604.28% to $275.5 million in 2024, then rose by 24.27% to $342.4 million in 2025, then decreased by 7.01% to $318.4 million in 2026.
• Business Quant data shows FDMT's Short-term Investments at $318.4 million in Q1 2026, $342.4 million in Q4 2025, and $256.5 million in Q3 2025.